Open tender · Germany · Contract notice
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Interferon beta-1b, ATC L03AB08 für die Zeit 01.04.2026 - 31.03.2028
DAK-Gesundheit in Germany is inviting bids for “Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Interferon beta-1b, ATC L03AB08 für die Zeit 01.04.2026…”. Bids close on 5 February 2028. To qualify, bidders need at least one similar completed work.
The work
Framework agreement for pharmaceutical rebate contracts for Interferon beta-1b for the period 01.04.2026 - 31.03.2028.
- Non-exclusive rebate agreement
- ATC L03AB08 for Interferon beta-1b
Key facts
- Contract period
- 01.04.2026 - 31.03.2028
- Evaluation
- Lowest price (L1) among technically qualified bids
- Submission
- Online, on the e-procurement portal
- Price basis
- predefined rebates
What it takes to qualify
Worth a closer look
- § 130a Abs. 8 SGB V
- 4. Teils des GWB
- Zulassungsmodells
Experience
- At least 1 similar work — Experience with pharmaceutical rebate agreements for Interferon beta-1b
Certifications and registrations
GST registration (optional)Not mentioned in the provided text
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- AngebotsschreibenLetter of offer
- Anerkennung der vertraglichen Maßgaben der DAK-GesundheitAcknowledgment of contractual terms, including rebates
- Anlage 1 zum VertragContract Annex 1
- Anlage 2 zum VertragContract Annex 2, listing the medicinal products